CTOs on the Move

CG Pharmaceuitcals

www.cgpharma.com

 
CG Pharmaceuitcals is a Emeryville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.cgpharma.com
  • 5858 Horton St Ste 265
    Emeryville, CA USA 94608
  • Phone: 510.594.8201

Executives

Name Title Contact Details

Similar Companies

Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. With accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.

Friendship Health and Rehab Center

Friendship Health and Rehab Center is a Roanoke, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advanced Enzyme Technologies

Advanced Enzyme Technologies Limited is engaged in business of manufacturing and sale of enzymes. The Companys geographical segments include Within India and Outside India. It provides solutions to industries, such as human healthcare and nutrition, a...

MustGrow Biologics

An #AG biotech company focused on providing natural, science-based biological solutions for high-value crops. CSE: MGRO | OTCQB: MGROF | FRA: 0C0

Unlearn

Founded in 2017, Unlearn.AI brings together a world-class team of experts across pharma, physics, machine learning, and business who share a vision of pioneering AI to eliminate trial and error in medicine. Unlearn is the only company creating TwinRCTsTM, which combine AI, prognostic digital twins, and novel statistical methods to run clinical trials requiring fewer patients in the control arm. Unlearn`s technology is used by leading global pharmaceutical companies, including Merck KGaA, Darmstadt, Germany, and has been published in conference abstracts and scientific journals, including Scientific Reports - Nature and The International Journal of Biostatistics. The European Medicines Agency qualifies Unlearn`s PROCOVA™ procedure, which provides the regulatory framework for the application of TwinRCTs to Phase 2 and 3 clinical trials.